Disease Flares Following COVID-19 Vaccination in Patients with Inflammatory Bowel Disease

Objective Flares of inflammatory bowel disease (IBD) can occur infrequently after vaccination for coronavirus disease 2019 (COVID-19), although the details of this phenomenon are poorly understood. To clarify the possibility of an unfavorable response in patients with IBD, we investigated IBD-related symptoms during the COVID-19 vaccination. Methods Between October 2021 and February 2022, we obtained the COVID-19 vaccination status of 411 IBD patients who were being treated at our institution. The disease course of IBD after vaccination was investigated in 188 patients with ulcerative colitis (UC) and 119 patients with Crohn's disease (CD) who had received at least one dose of the vaccine during the clinical remission phase. The baseline characteristics before vaccination were compared between the patients with UC with or without disease flares. Results During the 30-day follow-up period, eight patients with UC (4.3%) and one patient with CD (0.8%) experienced disease flares following vaccination. Disease flares occurred after the first vaccination in six patients and after the second vaccination in three patients. As for the timing of onset of disease flares, eight events (88.9%) occurred within one week of vaccination. Two patients required hospitalization, and one patient with CD required surgery for an intra-abdominal abscess. The baseline characteristics did not significantly differ between patients with UC who experienced flares and those who did not. Conclusion IBD flares following COVID-19 vaccination are rare and vaccination should therefore be recommended for patients with IBD. However, the possibility of disease flares should be considered for approximately one week after each vaccination, especially in patients with UC.

[1]  A. Masamune,et al.  Prolonged Diarrhea Following COVID-19 Vaccination: A Case Report and Literature Review. , 2022, The Tohoku journal of experimental medicine.

[2]  S. Sebastian,et al.  Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis , 2022, Digestive and Liver Disease.

[3]  M. Kudo,et al.  A Case of Ulcerative Colitis Relapse Characterized by Systemic Type I Interferon Responses after COVID-19 Vaccination , 2022, Inflammatory bowel diseases.

[4]  M. Nojima,et al.  DOP24 Japan prospective multicenter study for optimization of COVID-19 vaccinations based on the immune response and safety profile in Inflammatory Bowel Disease patients: Interim analyses of the J-COMBAT trial , 2022, Journal of Crohn's & Colitis.

[5]  M. Dubinsky,et al.  Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID , 2021, Inflammatory bowel diseases.

[6]  I. Dotan,et al.  COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation , 2021, Clinical Gastroenterology and Hepatology.

[7]  S. Carmagnola,et al.  Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD , 2021, Gut.

[8]  Yusuke Suzuki,et al.  Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan , 2021, Clinical and Experimental Nephrology.

[9]  I. Garrido,et al.  Safety of COVID-19 Vaccination in Inflammatory Bowel Disease Patients on Biologic Therapy , 2021, Gastroenterology.

[10]  N. Freund,et al.  Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα , 2021, Gastroenterology.

[11]  J. Singh,et al.  Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey , 2021, RMD Open.

[12]  A. Swaminath,et al.  SARS-CoV-2 Immunization in Patients With Inflammatory Bowel Disease May Result in Disease Flares. , 2021, The American journal of gastroenterology.

[13]  J. Tregoning,et al.  Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape , 2021, Nature reviews. Immunology.

[14]  N. Teich,et al.  SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease—Fear and Desire , 2021, Inflammatory bowel diseases.

[15]  D. Unutmaz,et al.  Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease , 2021, medRxiv.

[16]  D. Kuter Exacerbation of immune thrombocytopenia following COVID‐19 vaccination , 2021, British journal of haematology.

[17]  D. McGovern,et al.  Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease , 2021, The American journal of gastroenterology.

[18]  Shruti Chaturvedi,et al.  COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria , 2021, Blood.

[19]  John Wang,et al.  A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination , 2021, Kidney International.

[20]  Hannah Ritchie,et al.  A global database of COVID-19 vaccinations , 2021, Nature Human Behaviour.

[21]  D. Klonoff,et al.  COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. , 2021, European review for medical and pharmacological sciences.

[22]  M. Dubinsky,et al.  SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting , 2021, Gut.

[23]  J. Gisbert,et al.  Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study , 2020, Journal of clinical medicine.

[24]  S. Ng,et al.  Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry , 2020, Gastroenterology.

[25]  S. Fowler,et al.  Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. , 2018, Inflammatory bowel diseases.

[26]  Anthony W Wang,et al.  Impact of Diagnostic Delay and Associated Factors on Clinical Outcomes in a U.S. Inflammatory Bowel Disease Cohort , 2017, Inflammatory bowel diseases.

[27]  T. Ali,et al.  Updates in vaccination: recommendations for adult inflammatory bowel disease patients. , 2015, World journal of gastroenterology.

[28]  G. D'Haens,et al.  Optimising monitoring in the management of Crohn's disease: a physician's perspective. , 2013, Journal of Crohn's & colitis.

[29]  D. Iliopoulos,et al.  Environmental triggers in IBD: a review of progress and evidence , 2018, Nature Reviews Gastroenterology & Hepatology.